Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro.
dendritic cells
drug delivery systems
flow cytometry
hepatitis B virus
human peripheral blood mononuclear cells
in vitro
influenza virus
microparticles
nanoparticles
subunit vaccines
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
18 Jul 2022
18 Jul 2022
Historique:
received:
08
06
2022
revised:
14
07
2022
accepted:
14
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Viral subunit vaccines are a safer and more tolerable alternative to whole inactivated virus vaccines. However, they often come with limited efficacy, necessitating the use of adjuvants. Using free and particle-bound viral antigens, we assessed whether size affects the uptake of those antigens by human monocyte-derived dendritic cells (Mo-DCs) and whether differences in uptake affect their capacity to stimulate cytokine production by T cells. To this end, influenza antigens and hepatitis B surface antigen (HBsAg) were covalently conjugated to polystyrene particles of 500 nm and 3 μm. Cellular uptake of the antigens, either unconjugated or conjugated, and their capacity to stimulate T cells within a population of human peripheral blood mononuclear cells (PBMCs) were measured by flow cytometry. Conjugation of both antigens to particles significantly increased their uptake by Mo-DCs. Moreover, both the 500 nm and 3 μm influenza conjugates induced significantly higher numbers of cytokine-producing CD4
Identifiants
pubmed: 35890185
pii: ph15070887
doi: 10.3390/ph15070887
pmc: PMC9321264
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union Seventh Framework Program 19 (FP7/2007-2013) Universal Influenza Vaccines Secured (UNISEC) consortium
ID : 602012
Organisme : Swiss National Science Foundation
ID : CRSII5_180323
Pays : Switzerland
Références
Pharm Res. 2003 Feb;20(2):221-8
pubmed: 12636160
Anal Biochem. 2005 Jan 1;336(1):132-4
pubmed: 15582568
Anal Biochem. 1977 Dec;83(2):346-56
pubmed: 603028
Vaccine. 2014 Jan 9;32(3):327-37
pubmed: 24295808
Int J Pharm. 2021 Apr 15;599:120422
pubmed: 33647407
J Control Release. 2001 Sep 11;76(1-2):59-71
pubmed: 11532313
J Control Release. 2015 Dec 28;220(Pt A):141-148
pubmed: 26437263
Pharm Res. 2008 Aug;25(8):1815-21
pubmed: 18373181
Biomaterials. 2007 Dec;28(35):5344-57
pubmed: 17825905
Expert Opin Drug Deliv. 2016;13(2):167-70
pubmed: 26578092
Int J Pharm. 2005 Sep 14;301(1-2):149-60
pubmed: 16023313
Drug Discov Today. 2011 Jul;16(13-14):569-82
pubmed: 21570475
J Control Release. 2010 Jun 1;144(2):118-26
pubmed: 20156497
Int J Pharm. 2005 Jul 25;298(2):315-22
pubmed: 15961266
Vaccines (Basel). 2017 Aug 09;5(3):
pubmed: 28792466
J Immunol. 1998 Dec 1;161(11):5855-61
pubmed: 9834064
PLoS Pathog. 2008 Aug 29;4(8):e1000138
pubmed: 18769719
Vaccine. 2011 Aug 11;29(35):5824-36
pubmed: 21718746
Pharm Dev Technol. 2011 Feb;16(1):65-74
pubmed: 20088679
Pharm Res. 2001 Mar;18(3):352-60
pubmed: 11442276
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Biotechniques. 2014 Jul 01;57(1):39-44
pubmed: 25005692
Future Sci OA. 2015 Nov 01;1(4):FSO63
pubmed: 28031915
Annu Rev Immunol. 2021 Apr 26;39:759-790
pubmed: 33710920
J Cell Mol Med. 2017 Sep;21(9):1668-1686
pubmed: 28244656
Hum Vaccin. 2008 Jan-Feb;4(1):44-9
pubmed: 18438105
J Control Release. 2016 Jul 28;234:124-34
pubmed: 27221070
Vaccines (Basel). 2016 Apr 19;4(2):
pubmed: 27104575
Int J Nanomedicine. 2014 Aug 13;9:3885-902
pubmed: 25152619
Vaccines (Basel). 2019 Nov 13;7(4):
pubmed: 31766202
PLoS Med. 2010 Mar 30;7(3):e1000245
pubmed: 20361020
Vaccine. 2002 Nov 22;21(1-2):67-77
pubmed: 12443664
Am J Respir Cell Mol Biol. 2013 Jul;49(1):67-77
pubmed: 23492193
J Immunol. 2004 Sep 1;173(5):3148-54
pubmed: 15322175
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547